达西珠单抗

达西珠单抗（INN：dacetuzumab；开发代号：SGN-40或huS2C6）是一种人源化单克隆抗体，^[1]正在开发用于治疗CD40阳性癌症，如非霍奇金淋巴瘤^[2]和血液恶性肿瘤。^[3]

达西珠单抗

单克隆抗体
种类	完整抗体
目标	CD40
临床资料
其他名称	SGN-40
ATC码	未分配
识别信息
CAS号	880486-59-9  Y
ChemSpider	none
UNII	UT59FF4T5X
化学信息
化学式	C6452H9964N1732O1998S42
摩尔质量	145,111.33 g·mol−1

该药物由西雅图遗传学（英语：Seagen）公司开发。^[4]

参考资料

1. Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.
2. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology. September 2009, 27 (26): 4371–7. PMID 19636010. doi:10.1200/JCO.2008.21.3017 .
3. Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current Opinion in Investigational Drugs. June 2009, 10 (6): 579–87. PMID 19513947.
4. Khubchandani, Sapna; Czuczman, Myron S.; Hernandez-Ilizaliturri, Francisco J. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current Opinion in Investigational Drugs (London, England: 2000). 2009-06, 10 (6) [2024-03-10]. ISSN 2040-3429. PMID 19513947. （原始内容存档于2024-03-10）.